A recent report by Evaluate MedTech released at the annual AdvaMed med tech conference in Chicago found that M&A deal value in the med tech sector grew by 363% year over year in the first half of 2014 to $30 billion.
A pilot program to remotely monitor blood pressure and weight for congestive heart failure patients is being expanded. The program shows how patients and healthcare providers can work together via technology to reduce hospital readmission.
History and science have joined forces. Canadian researchers have discovered and identified a heart and gut disease caused by a genetic mutation that can be traced back to the 12th century Vikings.
NanoString Technologies is teaming up with Brigham and Women's Hospital to study genomic biomarkers and develop diagnostic tests for cancer, furthering the company's plans for accelerated growth.
Unilife, the injectable technology provider, has inked a deal with Sanofi to be the French drugmaker's sole provider of cartridge-based wearable injectors for the next 15 years.
GE has appointed John Flannery as the president and CEO of GE Healthcare. He was previously the SVP of business development at the company. The move comes after the healthcare division shrank a bit during the first half.
Medical retinal imaging player Optos, the U.K. National Health Service and academics will participate in a £10 million ($16 million) collaboration to enable earlier detection of eye diseases that threaten vision.
Scientists have discovered a blood biomarker useful in identifying patients at risk for developing diabetes.
Wearble health monitors might soon become a thing of the past--replaced by science fiction-sounding "invisibles." Futuristic implantable microchips are shaping up to be the cutting-edge way to monitor health. The idea is to make digital health monitoring a little less all-consuming.
Amid growing competition in the neuromodulation field, California devicemaker Nevro filed plans for an initial public offering valued at up to $115 million to ramp up development of its innovative pain-management implant.
Inversion mania seems to be dying down, but med tech merger mania continues. In the latest development, Becton Dickinson announced over the weekend that it will acquire Carefusion for $12.2 billion in a bid to save costs and broaden the company's offerings to hospitals.
An attorney whose practice is focused on medical device law has called into question the FDA's authority to regulate devices that are promoted on social media platforms like Facebook and Twitter.
Alere management is in advanced talks to sell its health management business, according to Reuters. In August, the diagnostics player had said it would do so before year-end as part of an ongoing strategic review aimed at returning the company to revenue and earnings growth.
Medtronic announced that it will fund its $43 billion acquisition of Ireland's Covidien using $16 billion in external financing instead of capital from its foreign subsidiaries. The tweak is in response to Treasury Department rules designed to discourage inversions.
Facebook is making more targeted efforts to dip into the medical industry.
As the med tech industry addresses a growing need for devices geared toward children, a Baltimore, MA-based physician is creating 3-D printed hands developed specifically for pediatric patients.
The European Union's antitrust unit is worried that Zimmer's $13.4 billion bid for crosstown rival Biomet will limit competition and wants to look into the deal further.
Glooko has launched a small device that plugs into more than 30 existing blood glucose meters that can transmit data wirelessly to a smartphone, allowing health systems and payers to collect data on their diabetes patients with the monitors they already have.
In a diversification bid, Charlotte, NC-based Carlisle Companies purchased Singapore's LHi Technology, a device industry supplier focused on cable manufacturing, for $195 million.
Women's fertility appmaker Glow raised $17 million to expand upon its launch a year ago, just as at-home pregnancy monitoring player BellaBeat rolled out three new products. Both 1-year-old startups are backed by high-flying tech VCs and are making sophisticated, consumer-friendly products aimed at helping women better manage and monitor their health that circumvent traditional healthcare providers.